DENTSPLY SIRONA INC (XRAY) Stock Fundamental Analysis
USA - NASDAQ:XRAY - US24906P1093 - Common Stock
11.83 USD
-0.39 (-3.19%)
11.83 USD
0 (0%)
Overall XRAY gets a fundamental rating of 4 out of 10. We evaluated XRAY against 191 industry peers in the Health Care Equipment & Supplies industry. XRAY has a medium profitability rating, but doesn't score so well on its financial health evaluation. XRAY is valued quite cheap, but it does not seem to be growing. Finally XRAY also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
XRAY had positive earnings in the past year.
In the past year XRAY had a positive cash flow from operations.
In the past 5 years XRAY reported 4 times negative net income.
In the past 5 years XRAY always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of -15.64%, XRAY is in line with its industry, outperforming 54.97% of the companies in the same industry.
XRAY has a Return On Equity (-48.42%) which is in line with its industry peers.
Looking at the Return On Invested Capital, with a value of 4.66%, XRAY is in the better half of the industry, outperforming 75.92% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for XRAY is below the industry average of 8.89%.
The 3 year average ROIC (4.11%) for XRAY is below the current ROIC(4.66%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.64% | ||
| ROE | -48.42% | ||
| ROIC | 4.66% |
ROA(3y)-10.01%
ROA(5y)-5.27%
ROE(3y)-25.27%
ROE(5y)-13.81%
ROIC(3y)4.11%
ROIC(5y)4.26%
1.3 Margins
XRAY has a Operating Margin of 7.87%. This is in the better half of the industry: XRAY outperforms 76.44% of its industry peers.
XRAY's Operating Margin has declined in the last couple of years.
XRAY has a Gross Margin of 51.92%. This is comparable to the rest of the industry: XRAY outperforms 45.55% of its industry peers.
XRAY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.87% | ||
| PM (TTM) | N/A | ||
| GM | 51.92% |
OM growth 3Y-25.8%
OM growth 5Y-12.74%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.16%
GM growth 5Y-0.95%
2. Health
2.1 Basic Checks
XRAY has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
XRAY has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, XRAY has less shares outstanding
Compared to 1 year ago, XRAY has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.05, we must say that XRAY is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 1.05, XRAY perfoms like the industry average, outperforming 53.40% of the companies in the same industry.
The Debt to FCF ratio of XRAY is 17.41, which is on the high side as it means it would take XRAY, 17.41 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 17.41, XRAY is in the better half of the industry, outperforming 71.73% of the companies in the same industry.
XRAY has a Debt/Equity ratio of 1.13. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of XRAY (1.13) is worse than 78.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.13 | ||
| Debt/FCF | 17.41 | ||
| Altman-Z | 1.05 |
ROIC/WACC0.75
WACC6.17%
2.3 Liquidity
XRAY has a Current Ratio of 1.69. This is a normal value and indicates that XRAY is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.69, XRAY is doing worse than 70.68% of the companies in the same industry.
XRAY has a Quick Ratio of 1.11. This is a normal value and indicates that XRAY is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of XRAY (1.11) is worse than 72.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.69 | ||
| Quick Ratio | 1.11 |
3. Growth
3.1 Past
XRAY shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.07%.
The Earnings Per Share has been decreasing by -7.38% on average over the past years.
XRAY shows a decrease in Revenue. In the last year, the revenue decreased by -5.78%.
The Revenue has been decreasing by -1.17% on average over the past years.
EPS 1Y (TTM)-7.07%
EPS 3Y-16.51%
EPS 5Y-7.38%
EPS Q2Q%6.12%
Revenue 1Y (TTM)-5.78%
Revenue growth 3Y-3.58%
Revenue growth 5Y-1.17%
Sales Q2Q%-4.88%
3.2 Future
XRAY is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.25% yearly.
XRAY is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.02% yearly.
EPS Next Y15.25%
EPS Next 2Y11.28%
EPS Next 3Y10.45%
EPS Next 5Y11.25%
Revenue Next Year-4.02%
Revenue Next 2Y-0.96%
Revenue Next 3Y0.26%
Revenue Next 5Y2.02%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 6.92, the valuation of XRAY can be described as very cheap.
Based on the Price/Earnings ratio, XRAY is valued cheaper than 96.34% of the companies in the same industry.
XRAY's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.02.
XRAY is valuated cheaply with a Price/Forward Earnings ratio of 5.72.
Based on the Price/Forward Earnings ratio, XRAY is valued cheaply inside the industry as 98.43% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of XRAY to the average of the S&P500 Index (22.57), we can say XRAY is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.92 | ||
| Fwd PE | 5.72 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of XRAY indicates a rather cheap valuation: XRAY is cheaper than 95.81% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, XRAY is valued cheaper than 87.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.1 | ||
| EV/EBITDA | 6.96 |
4.3 Compensation for Growth
XRAY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.45
PEG (5Y)N/A
EPS Next 2Y11.28%
EPS Next 3Y10.45%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 5.17%, XRAY is a good candidate for dividend investing.
The stock price of XRAY dropped by -27.02% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
XRAY's Dividend Yield is rather good when compared to the industry average which is at 1.82. XRAY pays more dividend than 100.00% of the companies in the same industry.
XRAY's Dividend Yield is rather good when compared to the S&P500 average which is at 2.44.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.17% |
5.2 History
On average, the dividend of XRAY grows each year by 11.21%, which is quite nice.
XRAY has been paying a dividend for at least 10 years, so it has a reliable track record.
XRAY has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)11.21%
Div Incr Years6
Div Non Decr Years30
5.3 Sustainability
The earnings of XRAY are negative and hence is the payout ratio. XRAY will probably not be able to sustain this dividend level.
The dividend of XRAY is growing around the same rate as the earnings are growing. If this keeps up the dividend growth is sustainable.
DP-13.49%
EPS Next 2Y11.28%
EPS Next 3Y10.45%
11.83
-0.39 (-3.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners104.22%
Inst Owner Change0.05%
Ins Owners0.32%
Ins Owner Change3.33%
Market Cap2.36B
Analysts70.43
Price Target16.96 (43.36%)
Short Float %4.46%
Short Ratio2.43
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.17% |
Yearly Dividend0.62
Dividend Growth(5Y)11.21%
DP-13.49%
Div Incr Years6
Div Non Decr Years30
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.27%
Min EPS beat(2)1.17%
Max EPS beat(2)45.37%
EPS beat(4)3
Avg EPS beat(4)2.65%
Min EPS beat(4)-40.52%
Max EPS beat(4)45.37%
EPS beat(8)3
Avg EPS beat(8)0.57%
EPS beat(12)6
Avg EPS beat(12)3.68%
EPS beat(16)8
Avg EPS beat(16)3.31%
Revenue beat(2)1
Avg Revenue beat(2)-0.45%
Min Revenue beat(2)-1.67%
Max Revenue beat(2)0.77%
Revenue beat(4)1
Avg Revenue beat(4)-1.31%
Min Revenue beat(4)-3.62%
Max Revenue beat(4)0.77%
Revenue beat(8)2
Avg Revenue beat(8)-1.89%
Revenue beat(12)5
Avg Revenue beat(12)-1.6%
Revenue beat(16)5
Avg Revenue beat(16)-1.99%
PT rev (1m)-0.99%
PT rev (3m)-7.85%
EPS NQ rev (1m)0.16%
EPS NQ rev (3m)-2.62%
EPS NY rev (1m)-0.1%
EPS NY rev (3m)-0.55%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.11%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.92 | ||
| Fwd PE | 5.72 | ||
| P/S | 0.64 | ||
| P/FCF | 17.1 | ||
| P/OCF | 8.34 | ||
| P/B | 1.2 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.96 |
EPS(TTM)1.71
EY14.45%
EPS(NY)2.07
Fwd EY17.48%
FCF(TTM)0.69
FCFY5.85%
OCF(TTM)1.42
OCFY11.99%
SpS18.4
BVpS9.83
TBVpS-3.51
PEG (NY)0.45
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.64% | ||
| ROE | -48.42% | ||
| ROCE | 5.89% | ||
| ROIC | 4.66% | ||
| ROICexc | 5.02% | ||
| ROICexgc | 12.12% | ||
| OM | 7.87% | ||
| PM (TTM) | N/A | ||
| GM | 51.92% | ||
| FCFM | 3.76% |
ROA(3y)-10.01%
ROA(5y)-5.27%
ROE(3y)-25.27%
ROE(5y)-13.81%
ROIC(3y)4.11%
ROIC(5y)4.26%
ROICexc(3y)4.36%
ROICexc(5y)4.5%
ROICexgc(3y)15.64%
ROICexgc(5y)20.94%
ROCE(3y)5.38%
ROCE(5y)5.49%
ROICexcg growth 3Y-31.16%
ROICexcg growth 5Y-12.42%
ROICexc growth 3Y-13.44%
ROICexc growth 5Y-4.44%
OM growth 3Y-25.8%
OM growth 5Y-12.74%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.16%
GM growth 5Y-0.95%
F-Score5
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.13 | ||
| Debt/FCF | 17.41 | ||
| Debt/EBITDA | 3.5 | ||
| Cap/Depr | 42.15% | ||
| Cap/Sales | 3.95% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 44.71% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.69 | ||
| Quick Ratio | 1.11 | ||
| Altman-Z | 1.05 |
F-Score5
WACC6.17%
ROIC/WACC0.75
Cap/Depr(3y)46.81%
Cap/Depr(5y)41.51%
Cap/Sales(3y)4.1%
Cap/Sales(5y)3.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.07%
EPS 3Y-16.51%
EPS 5Y-7.38%
EPS Q2Q%6.12%
EPS Next Y15.25%
EPS Next 2Y11.28%
EPS Next 3Y10.45%
EPS Next 5Y11.25%
Revenue 1Y (TTM)-5.78%
Revenue growth 3Y-3.58%
Revenue growth 5Y-1.17%
Sales Q2Q%-4.88%
Revenue Next Year-4.02%
Revenue Next 2Y-0.96%
Revenue Next 3Y0.26%
Revenue Next 5Y2.02%
EBIT growth 1Y5.86%
EBIT growth 3Y-28.45%
EBIT growth 5Y-13.75%
EBIT Next Year53.77%
EBIT Next 3Y18.64%
EBIT Next 5Y12.9%
FCF growth 1Y-30.3%
FCF growth 3Y-18.29%
FCF growth 5Y-11.45%
OCF growth 1Y-15.27%
OCF growth 3Y-11.14%
OCF growth 5Y-6.32%